This week in cardiology from heartwire
View all columns »-
Hormone therapy and MI; Durata, Riata ST Optim lead analysis; no benefit of fish oil; long-term PROTECT-AF analysis
Posted May 17, 2013 12:50 EDT -
ESC on anticoagulants; FDA on Liptruzet; Midei suit; MitraClip
Posted May 10, 2013 11:55 EDT -
Vitamin D; cardiologists' pay; intestinal flora; Kcentra
Posted May 3, 2013 16:00 EDT -
Canagliflozin; PURE; low-glycemic and Mediterranean diets
Posted Apr 26, 2013 11:55 EDT -
#187: Beet this: More evidence of BP-lowering effects of dietary nitrate; amiodarone-cancer link reemerges in observational study; ACE inhibitor, beta-blocker may thwart cardiotoxicity from chemotherapy; will new FDA meeting on Avandia prompt withdrawal?
1 COMMENT | Posted Apr 19, 2013 12:55 EDT -
#186: Prasugrel noninferior to ticagrelor, but both achieve poor platelet inhibition at two hours; REVIVEd in print: REVIVE levosimendan trials finally get peer-review validation; nonsystem issues prolong door-to-balloon times, up mortality in primary PCI
Posted Apr 12, 2013 16:55 EDT -
#185: Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists
Posted Apr 5, 2013 16:15 EDT -
#184: Rivaroxaban gets ACS indication recommendation from European regulators; MitraClip narrowly passes major test with FDA advisory panel; new oral anticoagulants in secondary stroke prevention: Apples and oranges?; EMA recommends restricting cilostazol
Posted Mar 28, 2013 14:25 EDT -
#183: Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin
Posted Mar 22, 2013 12:25 EDT -
#182: ACC 2013: Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks; PREVAIL yanked from ACC program; Watchman device meets safety end point; Niacin full results in HPS2-THRIVE; Another strike for digoxin in AF
Posted Mar 13, 2013 19:00 EDT -
#181: What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS
Posted Mar 7, 2013 12:12 EST -
#180: "Choosing wisely" now targets over 130 dubious tests, therapies; HPS2-THRIVE: High myopathy risk with niacin/laropiprant; unrestricted Mediterranean diets beat low-fat advice for primary CVD prevention; large proportion of raised LDL cholesterol...
Posted Mar 1, 2013 14:30 EST -
#179: NJ cardiologist received more than $100 000 in referral kickbacks; deaths doubled with high calcium intake plus supplements; widely used diclofenac associated with increased risk of CV events; functional evaluation of CAD using angiographic images
Posted Feb 22, 2013 10:50 EST -
#178: Short course of aspirin, clopidogrel cuts stroke risk; Lp(a) gene variant associated with aortic stenosis; MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients; weight-loss drug Qsymia improves cardiovascular risk profile
Posted Feb 15, 2013 13:25 EST -
#177: Runner who died during London Marathon took stimulant DMAA during race; weight-loss myths refuted in new review; new AHA/ASA guidelines for acute stroke treatment; slight risk of QT-interval prolongation found with two antidepressants
Posted Feb 8, 2013 10:25 EST -
#176: No benefit to dual RAS blockade in meta-analysis; metabolic syndrome in 40s linked to TV, lack of exercise, at age 16; Canadian Riata experience: Electrical failures eclipse externalized cables; "napkin-ring sign" on CT identifies high-risk coronary
Posted Feb 1, 2013 10:45 EST -
#175: Apixaban approved: Now, which anticoagulant to use?; darbepoetin alfa disappoints in RED-HF; suspect thrombus with signs of early valve degeneration after TAVI; half of cardiology practices now integrated with hospitals
Posted Jan 25, 2013 11:20 EST -
#174: Niacin/laropiprant products to be suspended; JNC 8, ATP 4 guidelines; new meta-analysis on sugar sparks old debate; two antihypertensives plus NSAID ups risk of acute kidney injury
Posted Jan 18, 2013 14:50 EST -
#173: Exercise woefully underutilized; lesser degrees of excess weight don't increase mortality; FDA approves apixaban for stroke prevention in nonvalvular AF; fructose intake may contribute to overeating
Posted Jan 11, 2013 14:40 EST -
#172: Biggest stories of 2012; AHA top-10 list; think you might have AF? There's an app for that; some diabetic patients may be overtreated with high-dose statins
Posted Dec 21, 2012 15:35 EST
-
#171: Dabigatran: Reassuring data on major bleeds; ACCOMPLISH BMI analysis doesn't mean obese hypertensives should get diuretics; AMPLIFY-EXT on apixaban in risk of long-term recurrent-VTE; aggressive smoking cessation; hands-only CPR/defibrillation
Posted Dec 14, 2012 15:25 EST -
#170: SCAI releases new consensus on "ad hoc" PCI; societies prepare interventionalists for new payment codes; heart-healthy diet additive to drug benefits in secondary prevention; increased mortality with digoxin in AF; warfarin for six months should be
Posted Dec 14, 2012 00:00 EST -
#169: Pall cast on Durata ICD lead as FDA document made public; "holistic" analysis shows domino effect of TAVI risk factors; CT coronary angiography identifies significant plaques in "normal" arteries; major bleeds with warfarin in AF are often fatal;
Posted Nov 30, 2012 00:00 EST -
#168: Diabetes risk outweighed by CV benefit of statins; "threshold" effect for vitamin D and CVD: New meta-analysis; European approvals for apixaban in AF, rivaroxaban for PE/DVT; New guidelines emphasize OMT for stable IHD; FDA approves HeartWare VAD
Posted Nov 23, 2012 00:00 EST -
#167: Dabigatran looks good long term: RELY-ABLE; occasional cocaine use can do acute and chronic damage; MADIT-RIT: Simple programming change averts most inappropriate ICD therapy; BLOCK-HF: Replace
Posted Nov 16, 2012 00:00 EST -
#166: CABG superior to PCI in diabetics in FREEDOM; impressive antihypertensive effect of flaxseed; what role for PFO closure?; TACT: Surprising, puzzling benefit from chelation therapy after MI; TRILOGY/ARCTIC: Back to the drawing board for platelet moni
Posted Nov 9, 2012 12:20 EST -
#165: What's hot at AHA 2012; PFO-closure trials RESPECT and PC miss primary end point; prasugrel bests clopidogrel in TRILOGY-ACS angiography cohort; RIVAL: Major benefits with radial PCI in STEMI vs NSTEMI; RF ablation, antiarrhythmic meds comparable as
Posted Nov 2, 2012 18:30 EDT -
#164: In diabetics, lifestyle management fails to reduce hard CV outcomes: Look AHEAD halted; rivaroxaban okayed for PE in Europe; PFO closure trials take spotlight at TCT 2012; small increased risk of CV events with diclofenac; FDA expands Sapien TAVI in
Posted Oct 26, 2012 13:30 EDT -
#163: HRT cuts CVD by 50%, latest "unique" data show; WSJ: St Jude knew of Riata lead flaws at end of 2005; MIST investigator accused of false data; pacemaker implants with CoreValve edge lower; NHANES: Lipid levels improve across US over 20 years
Posted Oct 19, 2012 13:45 EDT -
#162: Beta blockers of no use in stable CAD; docs debate valve choice; Montreal cardiologist suspended; adherence to warfarin-adjustment algorithm sharpens anticoagulation: RE-LY; CV risk prediction: CRP, fibrinogen add modestly
Posted Oct 12, 2012 09:00 EDT -
#161: Single-drug polypharmacy; dabigatran use climbing in US; consistent benefit of apixaban: ARISTOTLE; sulfonylurea cardiotoxicity probed; Bonhoeffer to be struck off medical register
Posted Oct 5, 2012 14:45 EDT -
#160: Statins and diabetes risk: More data; clopidogrel poststenting: The case for shorter duration, interruptions; EMA supports apixaban for AF/stroke; statins do not reduce the risk of VTE: New meta-analysis; rethinking routine testing of chest-pain pat
Posted Sep 28, 2012 16:40 EDT -
#159: Renal denervation cost-effective for resistant hypertension; no CV benefit of omega-3 fatty acids: Meta-analysis; doing nothing about CVD will cost $47 trillion; decline in nuclear tests per patient; restless legs linked to CHD
Posted Sep 21, 2012 14:10 EDT -
#158: NSAID risk persists five years post-MI; Obesity paradox strengthened by new SCAAR data in ACS; RELY finds dabigatran bleeding-related gene variant; Antihypertensive use in pregnancy up; Door-to-activation times drives PCI delays
Posted Sep 14, 2012 14:18 EDT -
#157: Chocolate reduces stroke risk in men; RE-LY Registry: Wide global variation in AF management, mortality; apixaban for AF patients with renal dysfunction?; CDC: US losing war against hypertension; ATLAS ACS 2 TIMI 51: 2.5-mg rivaroxaban cuts cardiac
Posted Sep 7, 2012 13:40 EDT -
#156: Results from ESC 2012; TRILOGY ACS: No win for prasugrel; WOEST: Drop aspirin in stent patients on oral anticoagulants; ALTITUDE: New data on why trial halted; PARAMOUNT phase 2; IABP SHOCK II; New European STEMI guidelines; HPS2-THRIVE
Posted Aug 31, 2012 12:00 EDT -
#155: ESC 2012: What's going to be hot; MIST investigator charges Circulation, AHA, with "breaking their own rules" on disclosure; FDA: Get X-rays of Riata lead; Meta-analysis challenges drug use in mild hypertension; PINNACLE-AF: slow uptake of new antic
Posted Aug 24, 2012 08:30 EDT -
#154: JUPITER analysis on diabetes risk with statins; statins linked to cataracts; chocolate nudges down BP in meta-analysis; bleeding risk tools compared in AF; troponin algorithm rules MI in or out in 77% of chest-pain patients
Posted Aug 17, 2012 11:20 EDT -
#153: AHA/ASA advisory on stroke prevention in AF; possible dabigatran, rivaroxaban antidotes; lip-cancer risk raised by photosensitizing antihypertensives; paper disputes MI count in TRITON, RECORD, and PLATO; US government investigates HCA hospitals
Posted Aug 10, 2012 12:55 EDT -
#152: Even nonobstructive CAD at CT predicts risk in symptomatic patients: CONFIRM; FDA approves EPA-only omega-3 PUFA capsule; Aggressive heart-rate control reduces radiation from CCTA; rivaroxaban gets NICE thumbs-up for DVT; BMJ: TAVI is overused
Posted Aug 3, 2012 14:30 EDT
-
#151: London 2012: Preventing SCD; CT-based FFR saves money by reducing PCIs; polypill for primary prevention: largest-yet reductions in BP, cholesterol in small trial; job stress strains women's hearts; workplace solvents linked to heart defects
Posted Jul 27, 2012 14:00 EDT -
#150: Higher HDL-particle concentrations associated with reduced CHD risk; HRT ups BP; risk of hypertension higher with longer duration of use; journal publishes spoof on AUC; "weekend effect" in stroke study; FDA approves new diet drug
Posted Jul 20, 2012 13:10 EDT -
#149: Apixaban delay prompts "not-us!" chorus; tighter UK food policies could slash CV deaths; echo vs nuclear for stress imaging after revascularization; NCDR registry: Many getting DES would do as well with BMS; ticagrelor tops prasugrel in pharmacodyna
Posted Jul 13, 2012 14:45 EDT -
#148: EVINCI: Invasive diagnostic tests can be dramatically reduced; cardiologists react to Supreme Court decision on ACA; readmission rates after MI not the best quality indicator?; rosiglitazone in healthcare-fraud case; 10-minute echo in young athlete
Posted Jul 6, 2012 11:50 EDT -
#147: No US approval yet for apixaban for stroke prevention in atrial fibrillation; FDA approves lorcaserin for the treatment of obesity; FDA refuses ACS indication for rivaroxaban?for now; Are statins less effective in women?
Posted Jun 29, 2012 13:36 EDT -
#146: Stem-cell findings strike at long-held vascular disease dogma; multibiomarker test for predicting CVD; Measuring apolipoproteins does not help risk prediction; First-in-human transcatheter mitral-valve implant
Posted Jun 22, 2012 14:10 EDT -
#145: Mortality benefit of running less than 20 miles per week; label update for dabigatran; who gets published?; alcohol may trigger AF episodes; FDA advisors: approve Sapien TAVR for high-risk operable patients
Posted Jun 15, 2012 11:45 EDT -
#144: Exercise worsens a CV risk factor in 10% of people; don't give up on HDL, researchers plead; major bleeding with aspirin in primary prevention underestimated; dietary calcium better than supplements; more evidence dark chocolate is cardioprotective
Posted Jun 8, 2012 10:40 EDT -
#143: Dabigatran fatal bleeding less than in trials; obesity paradox in ACCOMPLISH; dulaglutide passes BP hurdle; DIG revisited: digoxin scrutinized anew; LDL-receptor mAb: more impressive data
Posted Jun 1, 2012 12:00 EDT -
#142: Statins benefit those at much lower CV risk; so long, Plavix; ARISTOTLE: Apixaban cuts stroke risk in all types of AF; Next-generation transcatheter aortic valve looks good; 2012 European HF guidelines
Posted May 25, 2012 12:15 EDT -
#141: Pfizer stops promoting Lipitor in US; moderate coffee intake protects against stroke; MagnaSafe: MRI with pacers, ICDs: Safe, a few minor issues; FAME II: FFR pinpoints stable CAD patients who do worse with OMT; whistleblower suit implicates Nissen
Posted May 18, 2012 11:35 EDT -
#140: Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate
Posted May 11, 2012 11:40 EDT -
#139: CHA2DS2-VASc score gives best prediction of stroke risk in AF; subcutaneous ICD: thumbs up from FDA; DES or bare-metal stents for primary PCI?; beware valve involvement in device-related infective endocarditis; CMS restricts TAVI coverage to experie
Posted May 4, 2012 13:40 EDT -
#138: FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers
Posted Apr 27, 2012 13:00 EDT -
#137: Big bonuses for cardiologists at OSU; higher glycated hemoglobin levels, better outcomes in HF with diabetes; losartan vs candesartan mortality risk in HF disputed; Italian soccer player dies on the pitch; Maryland to set up independent PCI review
Posted Apr 20, 2012 15:00 EDT -
#136: COURAGE angle for NY analysis of PCI vs meds in stable CAD; many left ventriculographies are unnecessary; persistent high cholesterol more likely in countries with poorer healthcare; statins in primary prevention
Posted Apr 13, 2012 12:17 EDT -
#135: Analysis extends dabigatran MI signal to other thrombin inhibitors; new oral anticoagulants in AF: What to do in clinical practice; Riata ICD lead failures: Short-circuit risk; "statins for all"; biodegradable-polymer DES: Solid four-year safety and
Posted Apr 5, 2012 14:00 EDT -
#134: Vorapaxar in TRA 2°P-TIMI 50; response time key in renal-denervation; rivaroxaban in EINSTEIN PE; levels of LDL cholesterol predate cancer cases; ASCERT CABG, PCI analysis; Canadian AF guidelines
Posted Mar 30, 2012 11:25 EDT -
#133: What's hot at ACC 2012; CLOSURE I published; few Americans achieve "ideal" CV health; varespladib phase 3 ACS trial halted early; life and community on an LVAD
Posted Mar 23, 2012 17:30 EDT -
#132: "Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey
Posted Mar 16, 2012 14:30 EDT
-
#131: Details help explain dabigatran bleeds in New Zealand; FDA moves on rivaroxaban and apixaban; ivabradine front-page UK news; TAVR program how-to; renal denervation and cardiac function
Posted Mar 9, 2012 15:55 EST -
#130: FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated
Posted Mar 2, 2012 15:15 EST -
#129: ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies
Posted Feb 24, 2012 10:40 EST -
#128: Factor Xa reversal: More hope; criticism of PCI appropriateness criteria; Mediator scandal in France: Over 1300 deaths; Indian echo project takes remote diagnosis global
Posted Feb 17, 2012 14:15 EST -
#127: Wine and chocolate: Flavonoid and polyphenol research; clopidogrel plus aspirin: No benefit for stroke prevention; wireless power delivery for LVADs; TRA 2°P: Vorapaxar meets end point but ups bleeding
Posted Feb 10, 2012 14:00 EST -
#126: Patient care concerns ignored, careers destroyed, claim docs; heart attack deaths plummet in three EU nations; "valve-on-a-stick" transaortic TAVI alternative to transfemoral; Vytorin US label updated; risk begins with middle-age risk factors
Posted Feb 3, 2012 15:50 EST -
#125: Cardiologists accused of defrauding Medicare; treat risk and not LDL-cholesterol targets; PLATO: PPI analysis "raises flag"; "recalled" Riata ICD leads: summit aims for guidance; statins: to prescribe or not to prescribe?
Posted Jan 27, 2012 13:30 EST -
#124: Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial
Posted Jan 20, 2012 14:50 EST -
#123: Obesity: Focus on excess calories; Informed consent in patient's death after stem-cell treatment; Dabigatran: New data on MI and ischemic events; Serum potassium targets in acute MI; RESPECT PFO/stroke trial completes enrollment
Posted Jan 13, 2012 17:00 EST -
#122: Top news in 2011--Apixaban win in ARISTOTLE; the heart can repair itself; dalcetrapib passes test in dal-VESSEL; FDA restricts simvastatin 80 mg; NIH stops AIM-HIGH; poor long-term outcomes post ablation of AF; caution with dabigatran in elderly; FD
Posted Dec 29, 2011 13:40 EST -
#121: Vitamin D fails again to affect CV mortality; more overstenting charges in Maryland; data show antihypertensive therapy prolongs life; ALTITUDE halted; RECOVER II on benefit of dabigatran in treatment of VTE
Posted Dec 23, 2011 11:45 EST -
#120: CardioMEMS implantable PA-pressure monitor rejected by FDA; iPad app streams real-time data; bleeding in AF: European consensus; concern over Pfizer's Lipitor deals; cardiologists support elective PCI without on-site CABG: Survey
Posted Dec 16, 2011 13:35 EST -
#119: Stents, ICDs, inappropriate? Then CMS won't pay; FDA investigating serious bleeding events with dabigatran; Generic atorvastatin now in US; CV risk negligible with COX-2 inhibitors but AF a possible concern; noncardiac chest pain
Posted Dec 9, 2011 14:50 EST -
#118: CONFIRM CT registry raises more questions; CHADS2 predicts AF problems; Batting Big Tobacco; 30-day readmissions following PCI
Posted Dec 2, 2011 14:21 EST -
#117: Dabigatran fatal bleeds; Vitamin D; Sodium J-curve; Erasmus MC fires Poldermans; postshock driving restrictions
Posted Nov 25, 2011 15:40 EST -
#116: "Bridging" anticoagulation may not be necessary in many; AIM-HIGH: Results raise controversy; ATLAS ACS 2: Low-dose rivaroxaban looks good; SATURN trial; US dabigatran label updated; FDA on fenofibrate
Posted Nov 18, 2011 13:45 EST -
#115: What's going to be hot at AHA; FDA approves rivaroxaban; FDA issues "safety communication" on fenofibrate; Study backs ACE inhibitors, ARBs for aortic regurgitation; AHA/ACCF hypertrophic cardiomyopathy guidelines
Posted Nov 11, 2011 15:00 EST -
#114: Cardiologist, are you fat, unfit, unmotivated?; BP meds more effective at night; FDA advisors recommend Vytorin; fludrocortisone flops for vasovagal syncope; FDA recommends Sapien valve
1 COMMENT | Posted Nov 4, 2011 15:45 EDT -
#113: Public Citizen on rivaroxaban; More registry data on Sapien and CoreValve; Endeavor and DAPT; PARADIGM on aspirin in primary prevention; Little consensus on CAD extent, severity
Posted Oct 28, 2011 14:40 EDT -
#112: Heart-failure hospitalizations and mortality fall; Conflicts of interest and guidelines; Clopidogrel patients on "inhibiting" drugs; Yale docs propose model for transparency; DES in erectile dysfunction
Posted Oct 21, 2011 14:50 EDT
-
#111: Northwestern University denies tenure to Myxo ring whistleblower; Aspirin: Not for stroke prevention in AF patients; Rivaroxaban in nonvalvular AF; Dabigatran: Australia issues bleeding warning; Clopidogrel-aspirin arm halted in SPS3 stroke trial
Posted Oct 14, 2011 15:45 EDT -
#110: ATLAS-2 on rivaroxaban in ACS; Same-day discharge after elective PCI; Treating clopidogrel hypersensitivity with steroids; Lowering LDL to below 70; Statin costs: brand-name vs generic
Posted Oct 7, 2011 10:50 EDT -
#109: EMA recommends restricting dronedarone; new European recommendations for rivaroxaban; more on possible ARB-lung cancer risk; "verbal-suggestion" placebo reduces chest pain, constricts arteries; CT predictive value gender differences
Posted Sep 29, 2011 14:10 EDT -
#108: Statin decisions in new-onset diabetes; possible rivaroxaban antidote; elective LVAD in advanced HF?; twice-daily aspirin: better platelet inhibition in diabetics; acute-HF early-warning system implant surprises
2 COMMENTS | Posted Sep 23, 2011 14:55 EDT -
#107: RITA better than radial artery for CABG; CV safety of diabetes drugs; gene studies great help for understanding hypertension; high-sensitivity troponin test rules out MI; SAMMPRIS: Meds alone beat stenting for intracranial stenosis
Posted Sep 16, 2011 16:05 EDT -
#106: Rivaroxaban for stroke prevention in AF: Thumbs-up from panel; SATURN: Tie rosuvastatin-atorvastatin; New ESC ACS guidelines; RUBY-1 on factor Xa inhibition in ACS; GRAVITAS: Platelet reactivity correlates with adverse events
Posted Sep 9, 2011 16:00 EDT -
#105: Apixaban shines in ARISTOTLE; Dalcetrapib in dal-VESSEL; Oxygen for MI; clopidogrel in PRODIGY; triglycerides in Cream and Sugar Study
Posted Sep 2, 2011 17:05 EDT -
#104: What will be hot at ESC; MESA JUPITER on CAC; High marks for novel LVEF-boosting agent; Dronedarone "dear doctor" letter; Rise in ICD and pacemaker infections
Posted Aug 26, 2011 09:10 EDT -
#103: Malpractice suits in cardiology; Unnecessary stenting: Hospital pays $1.8 million; NICE HF guideline: Difficult questions; ROCKET-AF published; Cancer vs CV disease: Money
Posted Aug 19, 2011 15:40 EDT -
#102: Caution with dabigatran in the elderly; drugs, money, glory: is cancer beating CV disease?; multivessel PCI during STEMI; Pfizer wants Lipitor sold OTC; silent-embolization concerns with RF ablation catheter
Posted Aug 12, 2011 16:30 EDT -
#101: Cochrane salt/BP message blasted; US on "triple-therapy" for AF patients with stents; RE-MEDY on dabigatran vs warfarin for VTE; benefits of exercise on CHD risk; statins and stroke of unknown cause
Posted Aug 5, 2011 14:30 EDT -
#100: PALLAS: Deaths doubled with dronedarone; fraud conviction for John McLean; high platelet reactivity with prasugrel; APPRAISE-2 on apixaban; all about cardiac rehabilitation
Posted Jul 29, 2011 16:25 EDT -
#99: Green light for TAVI device from FDA advisors; ticagrelor approved for US market; chronic NSAID use doubles CV deaths in elderly; Parsemus Foundation on appropriate PCI; nuclear cardiology reports frequently omit information
Posted Jul 22, 2011 14:10 EDT -
#98: Mark Midei's medical license revoked; bleeding consensus and new definition; OAT, guidelines, and late PCI; nesiritide ASCEND-HF now in print; EMA adds CV events to review of dronedarone
Posted Jul 15, 2011 15:50 EDT -
#97: Niacin after AIM-HIGH, FDA on rivaroxaban, advice on salt in diet; varenicline and CV risk; dronedarone trail suspended: PALLAS
Posted Jul 8, 2011 15:40 EDT -
#96: Low-dose aspirin with ticagrelor; new ACC/STS recommendations for TAVI; soaring diabetes rates; new EAS advice on high triglycerides/low HDL; budget barriers for ICDs in Europe
Posted Jun 30, 2011 14:30 EDT -
#95: High-dose statins and diabetes; diastolic dysfunction echo predicts mortality in ACS; Chantix may increase CV events; door-in, door-out time for STEMI; Cordis quits coronary stent business
Posted Jun 23, 2011 14:45 EDT -
#94: Government joins cardiologist's fraud suit; FDA updates pioglitazone safety review; changes to QRS eligibility criteria for CRT urged; helping the heart repair itself; surfactant protein-D as biomarker
Posted Jun 17, 2011 14:55 EDT -
#93: Simvastatin 80 mg restricted by FDA; dabigatran cost-effectiveness depends on risk, INR control; FDA: No cancer risk with ARBs; SHARP on ezetimibe/simvastatin; systolic BP target in diabetes
Posted Jun 10, 2011 14:40 EDT -
#92: Revisiting dabigatran dose in the US?; terutroban no better than aspirin; polypill data predict halving of CV events; ticagrelor approved in Canada; rivaroxaban in secondary stroke prevention
1 COMMENT | Posted Jun 3, 2011 15:30 EDT
-
#91: More controversy for ezetimibe; NIH stops AIM-HIGH; apixaban approved in Europe; DHA, EPA, and LDL cholesterol; high heart rate: Culprit or bystander in heart failure?
Posted May 27, 2011 11:20 EDT -
#90: Cardiologist buys Arkansas Heart Hospital; FDA releases rosiglitazone REMS document; Fenofibrate panel; DISCOVER FLOW: Noninvasive FFR added to CT; RECLOSE 2 ACS: High platelet reactivity linked to higher deaths
Posted May 20, 2011 10:30 EDT -
#89: COURAGE findings not implemented; MitraClip recalled; FDA expands indication for carotid stenting; PARTNER A: Stroke with TAVI speaks to arteriosclerotic burden, baseline risk; surgeons on PARTNER A stroke data
Posted May 13, 2011 11:15 EDT -
#88: Cardiology salaries high, but high enough?; aspirin in primary prevention: New meta-analysis; salt paper causes controversy; CABG down, PCI stable; Emory cardiologists investigated for falsification
Posted May 6, 2011 13:40 EDT -
#87: DES costs Medicare $1.57 billion/year; JAMA letters question ICD-appropriateness study; edoxaban earns VTE indication in Japan; LANCELOT-CAD and ACS; ACC/AHA on hypertension in elderly
Posted Apr 29, 2011 11:05 EDT -
#86: Calcium supplements and CV risk; FDA on olmesartan benefits; low LDLs in JUPITER; AHA statement on triglycerides; refuting alleged ARB-cancer link
1 COMMENT | Posted Apr 21, 2011 10:50 EDT -
#85: RADAR: Novel anticoagulation system; Dabigatran 150mg twice daily; the Rheos system; Lost in transition: Grown-up congenital heart disease; FDA explains decision on dabigatran dose
Posted Apr 15, 2011 15:50 EDT -
#84: TAVI matches surgery in PARTNER cohort A; PARTNER B cost-effectiveness; MAGELLAN on rivaroxaban in acute medical patients; EVEREST II: MitraClip less effective but safer than surgery; STICH on CABG in HF patients; EXCELLENT on duration of DAPT
Posted Apr 8, 2011 11:25 EDT -
#83: Hot topics at ACC 2011; noninvasive CV imaging for subclinical disease; Elizabeth Taylor and the MitraClip; new appropriateness criteria to minimize echo misuse; UA/NSTEMI focused update
Posted Apr 1, 2011 11:00 EDT -
#82: TRIGGER-PCI halted; fibrate use on the rise; more on rosiglitazone; SYNTAX QoL; CAC, hs-CRP, and risk prediction; apixaban clears EU hurdle
Posted Mar 25, 2011 13:55 EDT -
#81: Debate continues on ticagrelor in PLATO; pocket-sized echo systems; latest on PPIs and clopidogrel; ROADMAP published; "apples" and "pears" in CV risk
Posted Mar 18, 2011 14:25 EDT -
#80: Five-year ACCORD results; ESC on substandard CV care in women; new obesity index proposed; DOSE on IV diuretics in acute HF; STEMI: Improvement from outside PCI hospital; LA cardiologist reports from Libya
Posted Mar 11, 2011 10:40 EST -
#79: Light to moderate drinking: Likely cardioprotective, but recommended?; Maryland government asked to oversee stenting; experts debate left main disease; Texas Heart Attack Prevention legislation; new devices to measure central aortic pressure
Posted Mar 4, 2011 16:10 EST -
#78: Consider all options for rosiglitazone switching; long road ahead to achieve CV health as defined by AHA; aspirin cost-effectiveness in primary prevention; SEAS analysis of aortic-stenosis severity; air pollution and MI
Posted Feb 25, 2011 15:09 EST -
#77: Diet soda and vascular-event risk; dabigatran (Pradaxa) joins US atrial-fib guidelines; 9p21 and CAD risk; WOSCOPS on association between obesity and CHD death; effects of dietary fiber on CV, all-cause death
Posted Feb 18, 2011 14:30 EST -
#76: Pradaxa in bottles must be used within 30 days; physicians on Barbara Walters special; JUPITER cost-effectiveness analysis; CHA2DS2-VASc score; global BMI, cholesterol, BP trends
Posted Feb 11, 2011 14:15 EST -
#75: FAST-MI on clopidogrel-PPI interaction; statins and CRP-new HPS data; no UK hypertension benefit from pay for performance; FDA sends Contrave back for CVD study; hybrid revascularization strategy
Posted Feb 4, 2011 10:00 EST -
#74: Cochrane statins controversy; no evidence for HCTZ as first-line therapy; SCD-HeFT on ICD protection post-MI; cardiac imaging radiation; should interventionalists treat MS?
Posted Jan 28, 2011 14:40 EST -
#73: FDA alert: Dronedarone and severe liver injury; hypertension success stories; CoreValve trial modification gets green light from FDA; genetic variants for CAD/MI; stopping antiplatelets post-DES implant ups events
Posted Jan 21, 2011 11:45 EST -
#72: ACCELERATE on hypertension; new HAS-BLED score; comparative effectiveness of dabigatran and warfarin; candesartan vs losartan in HF registry; genome scans and behavior
Posted Jan 14, 2011 15:30 EST
-
#71: ICD implants "non-evidence-based" in 25% of recipients; PLATO CABG published; cholesterol, triglyceride risk status in childhood vs adulthood; AHA and ASA highlight top 10 advances of the year; long-term AF ablation outcomes
Posted Jan 7, 2011 10:56 EST -
#70: New oral anticoagulants: How do they compare?; aromatase inhibitors may increase CV risk; new dabigatran safety data from RE-LY; European regulators explain rosiglitazone suspension; PROTECT-II
Posted Dec 17, 2010 14:30 EST -
#69: Finance Committee links Midei and Abbott in "potential fraud"; ventricular squeezing device, RESTOR-MV; EINSTEIN data debated; apixaban in hip/knee surgery; FDA on Contrave diet drug
Posted Dec 10, 2010 14:55 EST -
#68: More "unnecessary-stenting" allegations; meta-analysis reassuring on ARBs and cancer; bleeding risks with dual antiplatelet therapy; ASCET on single antiplatelet therapies; ethyl-EPA in MARINE
Posted Dec 3, 2010 15:10 EST -
#67: SHARP: Ezetimibe/simvastatin in renal disease; APPRAISE-2 (apixaban) ACS trial halted; ASCOT analysis fuels debate over JUPITER; benfluorex linked to hospitalizations, deaths for valvular disease; JUPITER-like MESA patients; CT angiography in CONFIRM
Posted Nov 26, 2010 14:55 EST -
Episode #66: Top news from AHA 2010 - EMPHASIS-HF: Eplerenone benefits in milder HF; rivaroxaban in ROCKET AF; ACC/AHA risk assessment guidelines; PFO closure in CLOSURE I; DEFINE on anacetrapib; renal denervation in Symplicity HTN-2; GRAVITAS
Posted Nov 19, 2010 14:05 EST -
Episode #65: Trials to look for at AHA 2010; Salt: Mandatory limits for most benefits; Vitamin-D analog could lower renal risk in diabetic nephropathy; High-risk JUPITER patients; PPIs and antiplatelets: Consensus
Posted Nov 11, 2010 18:40 EST -
Episode #64: Dabigatran questions answered; Canadian antiplatelet guidelines; Cough with ACE inhibitors underreported in labels and PDR; Sudden death of Argentina's past president poststenting prompts questions, fears; ROCKET AF
Posted Nov 5, 2010 14:55 EDT -
Episode #63: Canadian AF guidelines updated; Mark Midei, facing lawsuits, sues hospital himself; BP testing at black-owned barbershops; searchable "doctor-dollars" database; obesity drug dilemma
Posted Oct 29, 2010 14:40 EDT -
Episode #62: Dabigatran approved for AF; Atkins diet debated in diabetes; aspirin paradox investigated; new PREDIMED data on Mediterranean diet; CoreValve trial gets green light from FDA
Posted Oct 22, 2010 14:00 EDT -
Episode #61: RENEW: Diet/exercise for severely obese; cardiologists cut back: ACC survey; COGENT published; a branded diet plan works; transfusions overused in CV surgery; dietary sodium is too high
Posted Oct 15, 2010 14:55 EDT -
Episode #60: JUPITER criticism addressed in full; all diabetics over 40 should be on statins; SHARP refocuses primary end point; criticism of new guidance on hypertension in blacks; live case demos get new code of conduct
Posted Oct 8, 2010 15:00 EDT -
Episode #59: Reaction to rosiglitazone decisions; atopaxar in LANCELOT-ACS; digesting PARTNER; ethnicity and CRP-guided statin therapy; ADDITION on intensive therapy in diabetes
Posted Oct 1, 2010 15:20 EDT -
Episode #58: TAVI beats standard care in PARTNER; dabigatran gets thumbs-up from FDA panel; rosiglitazone can stay, says FDA, but EMA withdraws it; prasugrel vs ticagrelor; clopidogrel-PPI interaction: mechanistic studies
Posted Sep 24, 2010 16:00 EDT -
Episode #57: FDA says restrict or withdraw Meridia; clopidogrel-PPI genetics; FDA rosiglitazone bias?; SYNTAX three-year results; HeartNet trial halted
Posted Sep 16, 2010 15:30 EDT -
Episode #56: Maryland cardiologist faces possible 40 years in prison; CURRENT-OASIS 7 published; Europe-specific guidance on AF; European guidelines recommend CRT for NYHA class 2 HF; NSAIDs and stroke
Posted Sep 9, 2010 13:30 EDT -
Episode #55: Top news from ESC 2010 Congress -- SHIFT on HR as target treatment in HF; gene testing in PLATO; AVERROES on apixaban and stroke; n-3 fatty acids in Alpha Omega; RE-LY INR analysis; CURE ACTIVE; and LESSON I
Posted Sep 3, 2010 15:25 EDT -
Episode #54: What's going to be hot at ESC 2010 Congress; Atrial fibrillation? Don't blame caffeine; JUPITER: Statin therapy effective in intermediate-risk, high-CRP patients; new troponin recommendations; AHA on CVD research in Asian Americans
Posted Aug 27, 2010 13:20 EDT -
Episode #53: Statins at McDonald's; CRESCENDO, rimonabant's "obituary," published; in-lab clopidogrel loading; chocolate for blood pressure too hard to stomach; experts debate value of measuring renin levels to guide hypertension therapy
Posted Aug 20, 2010 16:00 EDT -
Episode #52: Platelet assay vs clopidogrel gene testing; SHAPE group proposes update to CAC, CIMT screening "guidelines"; coronary calcium controversy continues; in-lab clopidogrel testing
Posted Aug 16, 2010 09:55 EDT
-
Episode #51: Calcium supplements boost heart-attack risk: Meta-analysis; new trials support hands-only CPR; rivaroxaban in EINSTEIN-DVT study; transradial PCI approach; Arizona Heart Institute woes
Posted Aug 6, 2010 13:25 EDT -
Episode #50: Ticagrelor panel; disagreement on metabolic syndrome; hope for better antidiabetic drugs; variability in dyspnea, edema predicts outcomes in HF; therapeutic window for clopidogrel
Posted Jul 30, 2010 15:40 EDT -
Episode #49: Lorcaserin and obesity; depression, ED, and CV disease; disparities in DES use; TG and waist predict CHD; most with CV disease can fly safely; TIDE enrollment suspended
Posted Jul 23, 2010 13:55 EDT -
Episode #48: Rosiglitazone - Mixed message from FDA advisory committee vote, day-1 data deluge at FDA; imaging radiation; self-monitoring of BP; INVEST BP analysis
Posted Jul 16, 2010 13:10 EDT -
Episode #47: ONTARGET analysis; screening for subclinical disease; proteinuria despite chronic RAS suppression; MedPAC report; PLANET I and II
Posted Jul 9, 2010 13:50 EDT -
Episode #46: JUPITER gets a battering, AVANDIA controversy spikes, EMA to review ARBs and cancer, clopidogrel response and cardiac death, ACC and AHA on clopidogrel label
Posted Jul 1, 2010 14:10 EDT -
Episode #45: EAS statement on Lp(a); INTERSTROKE presented at WCC; ROADMAP: Experts on FDA review of olmesartan; ASE discussions of echocardiography; uncertain future for Rheos system
Posted Jun 25, 2010 17:30 EDT -
Episode #44: AVERROES stopped early; modest lung-cancer signal with ARBs; FDA reviews olmesartan safety record; RE-NOVATE 2; oxygen in MI queried
Posted Jun 18, 2010 15:15 EDT -
Episode #43: Favorable trend in US MI rates; diclofenac has similar CV risk to rofecoxib; gout drug allopurinol promising in chronic stable angina; bleeding risk score; aspirin and diabetes
Posted Jun 11, 2010 13:40 EDT -
Episode #42: Clopidogrel nonresponsiveness assays beat testing for CYP2C19; CREST published but stenting vs surgery debate continues; CHAMPION: sensor implant guides cut hospitalization; PPIs, clopidogrel, and stents; raised HDL and CRP is bad news
Posted Jun 4, 2010 14:35 EDT -
Episode #41: SOURCE reports Sapien transcatheter valve survival improving; metabolic syndrome relevance?; RESOLUTE: Zotarolimus-eluting "DES-strong" matches Xience at one year; sex post-MI?; No risk of cancer with statins according to observational study
Posted May 28, 2010 17:40 EDT -
Episode #40: AF ablation and Alzheimer's; new polypill trial in Europe; interaction of supplements with warfarin; can platelet-function tests help personalize antiplatelet therapy?; vernakalant bests amiodarone
Posted May 21, 2010 13:20 EDT -
Episode #39: Nuts improve lipid levels; ACCORD BP and hypertension targets; Jeopardy! at HRS; EuroASPIRE III on failures in prevention; triglycerides and CHD
1 COMMENT | Posted May 14, 2010 13:15 EDT -
Episode #38: Same-day discharge with radial PCI, azilsartan will be paired with chlorthalidone, CMSS code for industry interactions, 10% of Americans have prehypertension and prediabetes, first clinical interpretation of a human genome "exemplar"
Posted May 6, 2010 13:31 EDT -
Episode #37: Clopidogrel reloading for PCI in chronic therapy patients, churning over TIDE, more on PPIs-clopidogrel, JUPITER analysis of elderly, recertification process for interventionalists
Posted Apr 30, 2010 14:40 EDT -
Episode #36: Sensationalizing research, FDA will consider halting TIDE, transcatheter valve-in-valve implant, STEMI treatment variations in Europe, IOM recommends FDA set new standards for salt
Posted Apr 23, 2010 15:10 EDT -
Episode #35: Still no answers in new review of clopidogrel/PPIs, Delaware insurance fight, adding plaque and IMT to risk factors, impact of kidney disease on CV outcomes, full ARBITER 6-HALTS results
Posted Apr 16, 2010 15:15 EDT -
Episode #34: IMPROVE-IT complete in 2013, challenging dronedarone's value in AF, Guidant pleads guilty in 2005 recall, risk models for PCI patients, Edwards scolded over late adverse-event reports
Posted Apr 9, 2010 14:45 EDT -
Episode #33: Omega-3 PUFAs' effect on sinus rhythm, TRITON mortality trends, more heat for aspirin in primary prevention, UK NICE reverses on dronedarone, CT padding
2 COMMENTS | Posted Apr 1, 2010 15:55 EDT -
Episode #32: Clopidogrel-PPI interaction probed again, BP and mortality in acute chest pain, Watchman delayed, simvastatin dose and risk of muscle injury, how to diurese in acute HF
Posted Mar 26, 2010 14:10 EDT
-
Episode #31: PLATO CABG analysis confuses, concern on FDA clopidogrel warning, intensive BP lowering futile in diabetics, ACCORD lipid study, EVEREST II: Mitral-clip, NAVIGATOR on CV risk reduction in prediabetics
Posted Mar 19, 2010 13:50 EDT -
Episode #30: What's going to be hot at ACC 2010? CAC warranty period, coffee and arrhythmia link, olmesartan and atheroma, moderate vs vigorous activities
Posted Mar 12, 2010 23:05 EST -
Episode #29: Aspirin and primary prevention, dabigatran benefits AF patients, stenting and endarterectomy show similar safety and efficacy for carotid stenosis, future of TAVI, COX-2 inhibitors and statins, Obama's lipids
Posted Mar 5, 2010 15:05 EST -
Episode #28: Fate of rosiglitazone, ticagrelor controversy, five-year ARTS-II study, anticoagulation postablation, POPULAR published
Posted Feb 26, 2010 14:35 EST -
Episode #27: Statin therapy and diabetes, ACC backs cardiologist for Congress, WSJ on COURAGE, new test for enoxaparin clotting time, chocolate and stroke, President Clinton gets stents
Posted Feb 19, 2010 13:50 EST -
Episode #26: FDA approves wider rosuvastatin label, religion and CV disease, cardiologist may win "big" in whistleblower case, UK cardiologists petition for dronedarone, best hospital rankings
Posted Feb 12, 2010 15:00 EST -
Episode #25: Diuretic-CCB combo and MI risk, early mitral-valve repair in asymptomatic patients, atrial septal pouch a potential generator of thrombus, delaying surgery after PCI prevents kidney injury, shaking salt
Posted Feb 5, 2010 14:30 EST -
Episode #24: "Clinical significance" in randomized trials, obesity link to ischemic-stroke risk, red yeast rice in statin-intolerant patients, low-carb diet vs drug/diet combo, shaking salt
Posted Jan 29, 2010 15:25 EST -
Episode #23: US healthcare reform, PLATO-Invasive, TAVI: low acute renal injury, primary-PCI delay time, ADA on HbA1c for diabetes diagnosis
Posted Jan 22, 2010 15:30 EST -
Episode #22: NHANES: one-third of Americans obese, panel to FDA on Nebivolol, prasugrel cost-effectiveness, effects of resting heart rate and exercise on deaths, SPECT tests
Posted Jan 15, 2010 14:00 EST -
Episode #21: AHA top 10 studies from 2009, skin cancer in heart-transplant patients, evidence that Lp(a) causes heart disease, CRP unlikely to be causal for CVD, VTACH
Posted Jan 11, 2010 10:45 EST -
Episode #20: Endovascular aortic repair, high-dose statin therapy, FDA advisory panel in favor of broadened rosuvastatin indication, intensive medical therapy in asymptomatic carotid stenosis
Posted Dec 18, 2009 14:00 EST -
Episode #19: CETP and risk of CV disease, enhanced response to clopidogrel predicts bleeding risk, debate over aspirin use in primary prevention, contraindicated meds in dialysis patients undergoing PCI, statin therapy in ACS patients treated with PCI
Posted Dec 10, 2009 16:00 EST -
Episode #18: Clopidogrel-PPI interaction, intensive statin therapy in ACS patients, added value to new CV risk predictors? CETP activity and risk of CV disease, ICD-recipient anxiety
Posted Dec 7, 2009 09:30 EST -
Episode #17: ALLHAT investigators on antihpertensive treatment, REDEEM, vitamin D and prevention, SCD-HeFT on how ICDs save lives, CT-STAT
Posted Nov 30, 2009 09:45 EST -
Episode #16: Special AHA wrap-up: ARBITER 6-HALTS, CHAMPION, ticagrelor in PLATO STEMI subanalysis, FAIR-HF, HEAAL, FDA alert on clopidogrel-PPI interaction, ACC/AHA update guidelines for STEMI and PCI
Posted Nov 20, 2009 14:00 EST -
Daily coverage from AHA: Wednesday, Nov. 18: Statins and risk of low HDL, RE-LY, CDC data show LDL screening rate remains stagnant, JCHF, ACC/AHA guidelines for STEMI and PCI, STICH, CT-STAT, ticagrelor
Posted Nov 19, 2009 21:25 EST -
Daily coverage from AHA: Tuesday, Nov. 17: CHAMPION, Massachusetts data on STEMI PCI with/without surgery, RECORD AF, FOCUS, Bypassing the Blues, HeartMate II, FAIR-HF, HEAAL, CASCADE, and POPE
Posted Nov 17, 2009 23:55 EST -
Daily coverage from AHA: Monday, Nov. 16: PACE, ARBITER 6-HALTS, PLATO STEMI subanalysis, PRINCE, REPLACE, HOPE
Posted Nov 16, 2009 19:45 EST -
Daily coverage from AHA: Sunday, Nov. 15: CHAMPION-PCI and CHAMPION-PLATFORM, EXPIRA, RAPTOR, PEPCAD 3, FRANCE Registry, Canadian confusion, POPULAR trial
Posted Nov 15, 2009 19:30 EST
-
Episode #15: Special pre-AHA: What will be hot? Walking speed and CV mortality, no benefits of aspirin for primary prevention in diabetics, European and US STEMI guidelines, low-cholesterol/cancer studies and causal link
Posted Nov 13, 2009 16:00 EST -
Episode #14: CABG in ROOBY: off-pump vs on-pump, cardiac risk: CAC scoring and SPECT, perioperative beta-blocker use in noncardiac surgery, plaque regression with niacin vs placebo, and lifestyle-based diabetes prevention
Posted Nov 6, 2009 13:55 EST -
Episode #13: BLOSSOM: lorcaserin, weight-loss and valvular hurdles, stent pioneer addresses DES makers, women: same heart-attack symptoms as men, ACCORD on glucose-lowering, MESA: pericardial fat over BMI as predictor of CHD
Posted Oct 30, 2009 11:40 EDT -
Episode #12: Calcium screening might miss soft plaques, risk models overestimate CVD risk in diabetic patients, thiazolidinediones, TYCOON and antiplatelet therapy with DES, and ACE inhibitors, ARBS in those with preserved LV function
Posted Oct 23, 2009 13:30 EDT -
Episode #11: Target HbA1c levels, diuretics for hypertension, coronary thrombosis - more than plaque rupture, joint statement on metabolic syndrome, and omega-3 PUFAs for heart failure
Posted Oct 16, 2009 12:15 EDT -
Episode #10: Diabetes and bariatric surgery, IRIS on early post-MI primary-prevention ICDs, incidental findings on cardiac CT, 20 000-patient DAPT clinical trial starts enrolling, new "principles" on authorship and COI from PhRMA
1 COMMENT | Posted Oct 9, 2009 12:20 EDT -
Episode #9: Guideline changes based on REVERSE and MADIT-CRT?, early statin therapy in ACS, PLATO-Invasive, PROSPECT, and COGENT
Posted Oct 2, 2009 18:30 EDT -
Episode #8: Direct from TCT 2009 and more: Guidelines for left main disease, ENDEAVOR IV, high CAC scores and the EISNER study, how to shave 10 years off your life, should patients go directly to a PCI-capable hospital?
Posted Sep 25, 2009 14:00 EDT -
Episode #7: Who should get CRT?, COI in funded trials, statin therapy after ACS, CV health of Americans, IMPROVE-HF reports on evidence-based outpatient care
Posted Sep 18, 2009 11:30 EDT -
Episode #6: Medical literature questioned, RE-LY subanalysis, aspirin for type 2 diabetes, CURRENT OASIS-7, ARB/ACE-inhibitor combo
Posted Sep 11, 2009 15:00 EDT -
Episode #5: Direct from ESC Congress 2009: KYOTO HEART, TRITON-TIMI 38, MADIT-CRT, GRACE, PLATO, and RE-LY
Posted Sep 4, 2009 07:49 EDT -
Episode #4: What's hot at ESC Congress 2009? LE MANS registry, radiation doses with imaging, gene variant affecting clopidogrel response, troponin assays improve early diagnosis of AMI
Posted Aug 28, 2009 12:30 EDT -
Episode #3: Transradial PCI, short-term acute-MI mortality, pharmacist-doctor teams for HF, access to mitral-valve surgery, rosiglitazone safety
Posted Aug 21, 2009 11:45 EDT -
Episode #2: Prognostic value of CAC scoring, prasugrel in patients who receive GP IIb/IIIa inhibitors, ACE inhibitors in CABG patients, the ezetimibe fallout, and heparin COI investigation
Posted Aug 14, 2009 13:30 EDT -
Episode #1: Fish oil, telmisartan, ACS patients with atherosclerosis, NAPLES II, and physician connectivity
Posted Aug 7, 2009 15:00 EDT
